Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Jounce Therapeutics stock

Learn how to easily invest in Jounce Therapeutics stock.

Jounce Therapeutics Inc is a biotechnology business based in the US. Jounce Therapeutics shares (JNCE) are listed on the NASDAQ and all prices are listed in US Dollars. Jounce Therapeutics employs 137 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Jounce Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – JNCE – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Jounce Therapeutics stock price (NASDAQ: JNCE)

Use our graph to track the performance of JNCE stocks over time.

Jounce Therapeutics shares at a glance

Information last updated 2022-06-25.
Latest market close$3.02
52-week range$2.76 - $9.81
50-day moving average $4.62
200-day moving average $6.90
Wall St. target price$13.83
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.98

Buy Jounce Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
Finder Award
Stocks, ETFs, Cryptocurrency
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Axos Bank Self Directed Investing
when you open an account and deposit at least $1500.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Jounce Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Jounce Therapeutics price performance over time

Historical closes compared with the close of $3.02 from 2022-07-01

1 week (2022-06-24) 7.86%
1 month (2022-06-01) -17.26%
3 months (2022-04-01) -57.70%
6 months (2021-12-29) N/A
1 year (2021-07-02) -53.68%
2 years (2020-07-02) -53.61%
3 years (2019-07-02) 4.76
5 years (2017-06-30) 14.03

Is Jounce Therapeutics stock undervalued or overvalued?

Valuing Jounce Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Jounce Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Jounce Therapeutics's EBITDA

Jounce Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $22.6 million.

The EBITDA is a measure of a Jounce Therapeutics's overall financial performance and is widely used to measure a its profitability.

Jounce Therapeutics financials

Revenue TTM $25.4 million
Gross profit TTM $-17,799,000
Return on assets TTM -24.51%
Return on equity TTM -43.43%
Profit margin 0%
Book value $3.66
Market capitalisation $144.7 million

TTM: trailing 12 months

Jounce Therapeutics share dividends

We're not expecting Jounce Therapeutics to pay a dividend over the next 12 months.

Jounce Therapeutics share price volatility

Over the last 12 months, Jounce Therapeutics's shares have ranged in value from as little as $2.76 up to $9.81. A popular way to gauge a stock's volatility is its "beta".

JNCE.US volatility(beta: 1.15)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Jounce Therapeutics's is 1.1497. This would suggest that Jounce Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Jounce Therapeutics overview

Jounce Therapeutics, Inc. , a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts. .

Frequently asked questions

What percentage of Jounce Therapeutics is owned by insiders or institutions?
Currently 20.04% of Jounce Therapeutics shares are held by insiders and 86.994% by institutions.
How many people work for Jounce Therapeutics?
Latest data suggests 137 work at Jounce Therapeutics.
When does the fiscal year end for Jounce Therapeutics?
Jounce Therapeutics's fiscal year ends in December.
Where is Jounce Therapeutics based?
Jounce Therapeutics's address is: 780 Memorial Drive, Cambridge, MA, United States, 02139
What is Jounce Therapeutics's ISIN number?
Jounce Therapeutics's international securities identification number is: US4811161011
What is Jounce Therapeutics's CUSIP number?
Jounce Therapeutics's Committee on Uniform Securities Identification Procedures number is: 481116101

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site